The state of California is embarking on a bold plan to produce its own insulin in order to reduce costs for consumers, but the plan is already challenged by price cuts from several existing manufacturers. In an investigation of the plan and its viability in a difficult market, the New York Times quotes Professor Jacob Sherkow, an expert in patent law and co-author of a JAMA editorial on the California plan. “The best-case scenario is that the CalRx plan provides some sunshine on a path forward to state interventions in curbing drug prices,” he told the Times.

Read the full article in the New York Times.